Aytu BioPharma, Inc.(AYTU)

Drug Manufacturers - Specialty & Generic · Denver, CO

$2.06+0.02 (+0.98%)

Delayed quote: Oct 6, 2026, 1:33 PM EDT

PE Ratio: N/A

Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.

The P/E ratio is N/A as of 2026-10-06T17:35:38.884Z.

Stored calculation inputs

Calculation as of: 2026-10-06T17:35:38.884Z.

Quote observation: 2026-10-06T17:33:12.000Z. Amounts in USD. The price header may show a later quote.

Quote price: 2.06
Unrounded diluted TTM EPS · period ending 2026-06-30: -1.6581

FMP input reference: 34d3acea87fa6ce77646ae7da5683b25b27ba1f8f215b5f9e1848d21fed1287f

Forward PE Ratio|PEG Ratio|P/B Ratio|EPS|All Metrics

AYTU PE Ratio Metrics

PE RATIO

N/A

AYTU Competitors' PE Ratio

AYTU

Aytu BioPharma, Inc.

Current

Market Cap

$22.11M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

LONA

LeonaBio, Inc.

vs AYTU

Market Cap

$22.36M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

RNTX

Rein Therapeutics Inc.

vs AYTU

Market Cap

$22.91M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

QNTM

Quantum BioPharma Ltd.

vs AYTU

Market Cap

$21.24M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

MODD

Modular Medical, Inc.

vs AYTU

Market Cap

$21.44M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

TXMD

TherapeuticsMD, Inc.

vs AYTU

Market Cap

$23.26M

PE Ratio

N/A

TTM Avg

89.23

3Y Avg

89.23

5Y Avg

89.23

KYNB

Kyntra Bio, Inc.

vs AYTU

Market Cap

$24.21M

PE Ratio

N/A

TTM Avg

2502.34

3Y Avg

2502.34

5Y Avg

2502.34

ABVC

ABVC BioPharma, Inc.

vs AYTU

Market Cap

$24.51M

PE Ratio

N/A

TTM Avg

2021.12

3Y Avg

2021.12

5Y Avg

2021.12

ATOS

Atossa Therapeutics, Inc.

vs AYTU

Market Cap

$24.54M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

PIII

P3 Health Partners Inc.

vs AYTU

Market Cap

$19.67M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	PE RATIO	TTM	3Y	5Y
Aytu BioPharma, Inc. (AYTU)	$22.11M	N/A	N/A	N/A	N/A
LeonaBio, Inc. (LONA)vs ›	$22.36M	N/A	N/A	N/A	N/A
Rein Therapeutics Inc. (RNTX)vs ›	$22.91M	N/A	N/A	N/A	N/A
Quantum BioPharma Ltd. (QNTM)vs ›	$21.24M	N/A	N/A	N/A	N/A
Modular Medical, Inc. (MODD)vs ›	$21.44M	N/A	N/A	N/A	N/A
TherapeuticsMD, Inc. (TXMD)vs ›	$23.26M	N/A	89.23	89.23	89.23
Kyntra Bio, Inc. (KYNB)vs ›	$24.21M	N/A	2502.34	2502.34	2502.34
ABVC BioPharma, Inc. (ABVC)vs ›	$24.51M	N/A	2021.12	2021.12	2021.12
Atossa Therapeutics, Inc. (ATOS)vs ›	$24.54M	N/A	N/A	N/A	N/A
P3 Health Partners Inc. (PIII)vs ›	$19.67M	N/A	N/A	N/A	N/A

P/E Comparison

Trailing P/E

N/A

Forward P/E

N/A

Forward P/E Calculation

View All Analyst Estimates

Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.

Calculation:

Current Price

$2.06

Forward EPS (Est.)

PE Ratio Formula & Definition

PE Ratio = Share Price / Diluted EPS (TTM)

The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

See the Lowest P/E Ratio Stocks ranking →

About Aytu BioPharma, Inc.

Aytu BioPharma, Inc. is a specialized pharmaceutical firm dedicated to advancing and marketing innovative therapeutic drugs and consumer health products, serving both domestic U.S. and international markets. Its commercialized portfolio includes several treatments for Attention Deficit Hyperactivity Disorder (ADHD): Adzenys XR-ODT, prescribed for patients aged 6 and up; Cotempla XR-ODT, tailored for individuals between 6 and 17 years old; and Adzenys ER, an oral liquid formulation also for those 6 years and older. Additionally, the company offers Karbinal ER, an oral carbinoxamine suspension for managing seasonal and perennial allergies. It also provides Poly-Vi-Flor and Tri-Vi-Flor, which are prescription vitamin supplements designed for infants and children with fluoride deficiencies. Other products include Tuzistra XR, a prescription cough suppressant oral suspension containing codeine polistirex and chlorpheniramine polistirex, and ZolpiMist, an oral spray indicated for addressing insomnia. Founded in 2015, the company was previously known as Aytu BioScience, Inc. before officially changing its name to Aytu BioPharma, Inc. in March 2021. Its corporate headquarters are located in Englewood, Colorado.

Denver, CO

76 employees

aytubio.com

Healthcare / Drug Manufacturers - Specialty & Generic

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
CEO: Joshua R. Disbrow

View full financials

NAME

MARKET CAP

PE RATIO

TTM

Aytu BioPharma, Inc. (AYTU)

$22.11M

N/A

LeonaBio, Inc. (LONA)vs ›

$22.36M

N/A

Rein Therapeutics Inc. (RNTX)vs ›

$22.91M

N/A

Quantum BioPharma Ltd. (QNTM)vs ›

$21.24M

N/A

Modular Medical, Inc. (MODD)vs ›

$21.44M

N/A

TherapeuticsMD, Inc. (TXMD)vs ›

$23.26M

N/A

89.23

Kyntra Bio, Inc. (KYNB)vs ›

$24.21M

N/A

2502.34

ABVC BioPharma, Inc. (ABVC)vs ›

$24.51M

N/A

2021.12

Atossa Therapeutics, Inc. (ATOS)vs ›

$24.54M

N/A

P3 Health Partners Inc. (PIII)vs ›

$19.67M

N/A

PE Ratio Formula & Definition

PE Ratio = Share Price / Diluted EPS (TTM)

The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.

PE Ratio: N/A

AYTU PE Ratio Metrics

AYTU Competitors' PE Ratio

P/E Comparison

Forward P/E Calculation

PE Ratio Formula & Definition

Related Metrics

PE Ratio: N/A

AYTU PE Ratio Metrics

AYTU Competitors' PE Ratio

P/E Comparison

Forward P/E Calculation

PE Ratio Formula & Definition

Related Metrics